About I2a
I2a is a Healthcare company based in Montpellier (France) founded in 1988 by Christian Curel, and was acquired by Apposite Capital in August 2021. Life sciences instruments, software, and reagents are manufactured for diagnostics. Its chief executive, as recorded, is Michel Emelianoff. I2a offers products and services including SIRxpert, SIRscan Orion, SIRscan Lynx, and SIRxpert MALDI-TOF. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Diversified. Its legal entity is Intelligence Artificielle Applications.
Company details
The company was founded in 1988 in Montpellier, France, and operates within the life sciences sector. Instruments such as the Anti biogram reader, Urine cytology system, and Slide scanner are produced, along with reagents and consumables. A software solution is provided for clinical microbiology management. Operations focus on supporting diagnostic processes in healthcare settings.
- Headquarters Montpellier, France
- Founders Christian Curel
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website i2a-diagnostics.fr
- Social LinkedIn X Facebook YouTube
- Acquired by Apposite Capital (Aug 2021)
- Legal Name Intelligence Artificielle Applications
- Investors
- Acquired byApposite Capital
(Aug 2021)
Products & Services of I2a
I2a offers a comprehensive portfolio of products and services, including SIRxpert, SIRscan Orion, SIRscan Lynx, and SIRxpert MALDI-TOF.
Manages microbiological data and integrates lab results.
Incubates and reads antibiograms for bacterial testing.
Performs semi-automatic antibiogram analysis in labs.
Integrates mass spectrometry for bacterial identification.
Apps and channels of I2a
its YouTube channel i2a Intelligence Artificielle Application has 40 subscribers and 11 videos.
Videos from I2a
The most watched videos on I2a's YouTube channel, i2a Intelligence Artificielle Application (40 subscribers). Click a video to play it here.
Investors in I2a
I2a has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Apposite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare impact investments are managed by Apposite Capital. | appositecapital.com | London, United Kingdom |
Investor details for I2a
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of I2a
2 people are tracked at I2a (2 in leadership).
| Name | Role | Group |
|---|---|---|
Christian Curel | Founder | Leadership |
Michel Emelianoff | CEO | Leadership |
Complete people profiles for I2a
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of I2a
2 dated milestones of I2a across 33 years, from founding to its latest funding, stage changes and deals.
- Founded I2a is founded.
- Exit Acquired by Apposite Capital.
Web traffic of I2a
The website of I2a (i2a-diagnostics.fr) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 129.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about I2a
I2a was founded in 1988.
I2a is headquartered in Montpellier, France. It is registered at Montpellier, Occitanie, France.
Michel Emelianoff is the CEO of I2a, as recorded in our data.
The company was founded in 1988 in Montpellier, France, and operates within the life sciences sector. Instruments such as the Anti biogram reader, Urine cytology system, and Slide scanner are produced, along with reagents and consumables. A software solution is provided for clinical microbiology management. Operations focus on supporting diagnostic processes in healthcare settings.
I2a offers SIRxpert, SIRscan Orion, SIRscan Lynx, and SIRxpert MALDI-TOF.
I2a has 1 investor. Key investors include Apposite Capital.
I2a operates through Intelligence Artificielle Applications.
Yes. I2a was acquired by Apposite Capital in August 2021.